Reconnect Labs develops precision neuropsychiatric therapeutics and predictive diagnostics targeting insomnia, anxiety, and substance use disorders. Their platform combines engineered psychoactive formulations with disease‑modifying mechanisms to deliver both rapid symptom relief and long‑term therapeutic benefit. Leveraging expertise in neuroscience, psychopharmacology, and clinical research, they aim to create scalable, cost‑effective treatments for mental health conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current pharmacological treatments for insomnia, anxiety, and substance use disorders often provide only symptomatic relief without addressing the underlying disease mechanisms. These treatments may also have limited long-term efficacy and fail to break the cycle of illness and maladaptive behaviors.
Solution
Reconnect Labs is developing precision therapeutics and predictive diagnostics for neuropsychiatric conditions, including insomnia, anxiety, and substance use disorders. The company engineers psychoactive compounds with precise therapeutic effects and focused molecular targets to deliver regenerative and cost-effective treatments. Their novel formulations aim to provide immediate symptom alleviation and durable, long-term disease modification. By leveraging expertise in neuroscience, psychiatry, and psychopharmacology, Reconnect Labs is building a platform of drug candidates with the potential to treat multiple sleep, anxiety, and substance use disorders.
Target Audience
The primary target audience includes individuals suffering from insomnia, anxiety, and substance use disorders, as well as the healthcare professionals who treat these conditions.
Features
- Engineered psychoactive compounds with therapeutically precise effects
- Targeted molecular action for long-term disease modification
- Predictive diagnostics to identify patients most likely to benefit from treatment
- Focus on regenerative and cost-effective treatments
- Pipeline of drug candidates for sleep, anxiety, and substance use disorders